RxDoctor Payments Data

Ahmar Butt, MD

Internal Medicine · Brooklyn, NYNPI 1619983871

Payments from drug & device makers

$1,810in general payments, 2019–2025

Across 93 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$390
  • Lilly USA, LLC$348
  • Global Blood Therapeutics, Inc.$251
  • AstraZeneca$196
  • Novo Nordisk$105
  • Pfizer$90
  • plus $430 from 11 others

What the payments were for

  • Food & beverage$1,810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,810 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$102,865
Medicare patients
208
Services billed
997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$59,196
EliquisApixaban98$47,201
XareltoRivaroxaban99$42,108
EntrestoSacubitril/Valsartan39$32,986
JanuviaSitagliptin Phosphate57$26,513
JardianceEmpagliflozin35$17,266
FarxigaDapagliflozin Propanediol20$14,676
TrulicityDulaglutide15$13,774
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$10,729
AbrysvoRsv Vacc, Pref A And Pref B/Pf26$8,261
LinzessLinaclotide12$6,851
Atrovent HfaIpratropium Bromide14$6,217
Sevelamer Carbonate15$6,170
Incruse ElliptaUmeclidinium Bromide17$5,917
Novolog FlexpenInsulin Aspart33$5,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$105$59,19649 claims
PfizerEliquis, Abrysvo$90$55,462124 claims
Johnson & JohnsonXarelto$61$42,10899 claims
NovartisEntresto$390$32,98639 claims
AstraZenecaFarxiga, Symbicort$196$17,97335 claims
Lilly USA, LLCTrulicity$348$13,77415 claims
AbbVieLinzess$67$6,85112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →